Business Model Breakdown
How Perrigo Company PLC Makes Money
PRGO
Market Cap
$1.6B
Annual Revenue
$8.4B
Profit Margin
-33.5%
The Short Version
Perrigo Company PLC is a global consumer self-care company that develops, manufactures, markets, and distributes a diverse portfolio of over-the-counter (OTC) health and wellness products, as well as infant formula. The company primarily sells its products to retailers and wholesalers, offering both its own branded products and private label (store brand) equivalents. Its business model relies on leveraging strong brand recognition, efficient manufacturing, and extensive distribution networks to capture market share in essential consumer health categories.
Where the Revenue Comes From
Consumer Self-Care Americas (~60-70% of revenue, estimated)
Consumer Self-Care International (~20-30% of revenue, estimated)
Infant Formula (under strategic review, ~5-10% of revenue, estimated)
Who buys: Retailers (e.g., pharmacies, supermarkets, mass merchandisers), wholesalers, and directly to consumers through various channels.
Why It Works (Competitive Advantages)
- ✔Strong brand recognition in specific OTC categories
- ✔Established retail partnerships and distribution network
- ✔Portfolio of essential self-care products with inelastic demand
Economic Moat: Narrow (Brand Power, Cost Advantages (from scale and efficiency in private label/generics), Intangible Assets/IP (limited patents, mostly related to specific OTC formulations))
What Our Analysis Says
DVR Score as of April 18, 2026
Perrigo continues to operate in a mature, highly competitive consumer self-care market, evident from its Q4 2025 revenue decline (-2.5% YoY) and significant net losses (-33.51% net margin). While the company maintains a stable balance sheet with positive free cash flow and a commitment to its dividend, its strategic focus on cost reduction (workforce cuts) and portfolio optimization (infant formula review) are typical of a defensive turnaround, not a high-growth investment. There is no evidence of disruptive innovation, hyper-scalability, or expanding competitive advantages that would support a 10x growth potential within 3-5 years. Analyst sentiment is predominantly negative ('Reduce'), and the median price target offers only modest upside, far short of the required exponential growth.